These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25055405)

  • 1. Weighing up the risks and benefits of androgen deprivation therapy.
    Rees J
    Practitioner; 2014 May; 258(1771):5. PubMed ID: 25055405
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system?
    Zhang K; Zhang L; Hao Z; Liang C
    World J Urol; 2016 Jun; 34(6):879-81. PubMed ID: 26424563
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved.
    Azvolinsky A
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000
    [No Abstract]   [Full Text] [Related]  

  • 4. Don't think once, think twice! the cardiovascular effects of androgen deprivation therapy.
    Jefferies ER; Thurairaja R; Persad RA; Rajani R; Phull JS; Bahl A
    BJU Int; 2011 Apr; 107(7):1023-8. PubMed ID: 21438973
    [No Abstract]   [Full Text] [Related]  

  • 5. Long term androgen deprivation therapy in prostate cancer.
    Ockrim JL; Abel PD
    BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586
    [No Abstract]   [Full Text] [Related]  

  • 6. Does the benefit justify the risk?
    Albertsen PC
    J Natl Cancer Inst; 2010 Jan; 102(1):4-5. PubMed ID: 19996059
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma].
    Kliesch S; Behre HM; Roth S
    Dtsch Med Wochenschr; 1997 Jul; 122(30):940-5. PubMed ID: 9280708
    [No Abstract]   [Full Text] [Related]  

  • 9. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater.
    Nguyen PL
    Eur Urol; 2014 Apr; 65(4):710-2. PubMed ID: 23498063
    [No Abstract]   [Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.
    Saylor PJ; Keating NL; Freedland SJ; Smith MR
    Drugs; 2011 Feb; 71(3):255-61. PubMed ID: 21319864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome and prostate cancer: a review.
    Nobes JP; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):183-91. PubMed ID: 19111451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of fracture after androgen deprivation for prostate cancer.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Schooling CM; Sembajwe G; Agalliu I
    Eur Urol; 2013 Sep; 64(3):e59-60. PubMed ID: 23623050
    [No Abstract]   [Full Text] [Related]  

  • 18. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 19. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 20. No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
    Evers J; Kupper N; Kessing D; Davits R; Engelen A; Poortmans P; Mols F
    Urology; 2010 Nov; 76(5):1150-6. PubMed ID: 20869105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.